1  PRODUCT NAME

XYLESTESIN-A 1/80 000 solution for injection

2.  QUALITATIVE AND QUANTITATIVE COMPOSITION

<table>
<thead>
<tr>
<th>Component</th>
<th>1 mL solution for injection contains</th>
<th>1.7 mL solution for injection contains</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active ingredients</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LIDOCAINE (LIGNOCaine) hydrochloride (as monohydrate)</td>
<td>20 mg</td>
<td>34 mg</td>
</tr>
<tr>
<td>ADRENALINE (EPINEPHRINE) hydrochloride (equivalent to Adrenaline (epinephrine))</td>
<td>15 micrograms</td>
<td>25.5 micrograms</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12.5 micrograms</td>
</tr>
<tr>
<td><strong>Excipients with known effect</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SODIUM SULFITE (E 221)</td>
<td>0.6 mg</td>
<td>1.02 mg</td>
</tr>
<tr>
<td>SODIUM*</td>
<td>1.71 mg</td>
<td>2.91 mg</td>
</tr>
</tbody>
</table>

*Sodium content of sodium sulfite and sodium chloride
For the full list of excipients, see section 6.1

3.  PHARMACEUTICAL FORM

Solution for injection

The solution is a clear, not opalescent, colourless liquid with a pH value of 3.6 to 4.4.

4.  CLINICAL PARTICULARS

4.1  Therapeutic indications

Local anaesthesia (infiltration and nerve-block anaesthesia) in dentistry. Xylestesin-A is indicated in adults, children and adolescents.

4.2 Dose and method of administration
Xylestesin-A is exclusively recommended for use in dentistry.

**Dose**
The smallest possible volume of solution which will lead to an effective anaesthesia should be used.

**Adults:**
The dosage should be determined on an individual basis according to the technique used and particularities of the specific case.
In oral infiltration and/or mandibular block, initial dosages of 1.0 – 4.0 mL are usually sufficient.

**Special populations:**
**Elderly population:** Increased plasma levels of Xylestesin-A can occur in older patients due to diminished metabolic processes and reduced distribution volume. The risk of accumulation of Xylestesin-A is particularly increased after repeated.
Dosages should be reduced from adult recommendations, taking into consideration any cardiac or liver disease (see section 4.4).

**Patients with hepatic impairment:** Lidocaine (lignocaine) is metabolised in the liver. Lower doses of lidocaine (lignocaine) may be required in patients with hepatic dysfunction due to prolonged effects and systemic accumulation. (see section 4.4).

**Patients with renal impairment:** Lidocaine (lignocaine) and its metabolites are mainly eliminated in urine. Lower doses of lidocaine (lignocaine) may be required in patients with severe renal dysfunction due to prolonged effects and systemic accumulation (see section 4.4).

**Other relevant special populations:** The dose has to be similarly reduced in patients with certain pre-existing diseases (angina pectoris, arteriosclerosis, see section 4.3 and 4.4) and patients concurrently taking medications known to interact with lidocaine (lignocaine) and/or adrenaline (epinephrine) see section 4.4 and 4.5).

**Dose recommendation for special populations:** A lower dosage range is thus recommended in all such cases (i.e. minimum volume of Xylestesin-A for sufficient anaesthetic effect).

**Paediatric population:**
Xylestesin-A is indicated in adults, children and adolescents. Special care has to be exercised when treating children below 4 years. The quantity to be injected should be determined by the age and weight of the child and the magnitude of the operation. The anaesthesia technique should be selected carefully. Painful anaesthesia techniques should be avoided. The behaviour of the child during treatment has to be monitored carefully. The average dose to be used is in the range of 20 mg to 30 mg lidocaine (lignocaine) hydrochloride per session. The dose in mg of lidocaine (lignocaine) hydrochloride which can be administered in children may alternatively be calculated from the expression: child’s weight (in kilograms) x 1.33.
Dose recommendation for children and adolescents:

<table>
<thead>
<tr>
<th>Body weight (kg)</th>
<th>Recommended dosage</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>lidocaine (lignocaine) hydrochloride mg/child</td>
<td>solution for injection mL/child</td>
</tr>
<tr>
<td>20 - &lt;30</td>
<td>5-20</td>
<td>0.25 mL – 1 mL</td>
</tr>
<tr>
<td>30- &lt;40</td>
<td>10-40</td>
<td>0.5 mL – 2 mL</td>
</tr>
<tr>
<td>40 - &lt;50</td>
<td>10 – 60 mg</td>
<td>0.5 mL – 3 mL</td>
</tr>
<tr>
<td>50 - &lt; 60</td>
<td>20 – 80 mg</td>
<td>1 mL – 4 mL</td>
</tr>
<tr>
<td>60 - &lt; 70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70 - &lt; 80</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Due to the fact that lidocaine (lignocaine) diffuses rapidly into tissues and the density of bones is lower in children compared to adults, infiltration anaesthesia instead of conduction anaesthesia can be preferred in paediatric population.

**Maximum Recommended Dosage:**

**Adults:**
For healthy adults, the maximum dose of the active ingredient lidocaine (lignocaine) hydrochloride with vasoconstrictor admixture is 7mg/kg body weight.

Example: The maximum dose for a 70 kg patient is 500 mg. However, due to the addition of adrenaline (epinephrine) 1:80,000, the maximum administered quantity of 16 mL solution for injection or 9 cartridges (equivalent to 0.2 mg adrenaline (epinephrine), maximum dose) must not be exceeded.

**Children:**
The quantity to be injected should be determined by the age and weight of the child and the magnitude of the operation. Do not exceed the equivalent of 5 mg lidocaine (lignocaine) hydrochloride /kg BW or 0.250 mL Xylestesin-A/kg BW.
Maximum recommended dosage of Xylestesin-A in children and adolescents:

<table>
<thead>
<tr>
<th>Body weight (kg) (Corresponding paediatric age groups according to ± limits of growth tables)</th>
<th>Maximum allowed dose based on 5 mg/kg BW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lidocaine (lignocaine) hydrochloride mg/child</td>
</tr>
<tr>
<td>20 - &lt;30</td>
<td>100</td>
</tr>
<tr>
<td>30 - &lt;40</td>
<td>150</td>
</tr>
<tr>
<td>40 - &lt;50</td>
<td>200</td>
</tr>
<tr>
<td>50 - &lt;60</td>
<td>250</td>
</tr>
<tr>
<td>60 - &lt;70</td>
<td>300</td>
</tr>
<tr>
<td>70 - &lt;80</td>
<td>350</td>
</tr>
</tbody>
</table>

**Method of administration**

Dental use

To avoid intravascular injection, aspiration control at least in two planes (rotation of the needle by 180°) must always be carefully undertaken, although a negative aspiration result does not safely rule out an unintentional and unnoticed intravascular injection.

The injection rate should not exceed 0.5 mL in 15 seconds, i.e. 1 cartridge per minute.

Major systemic reactions as a result of accidental intravascular injection can be avoided in most cases by an appropriate injection technique – after aspiration of slow injection of 0.1 – 0.2 mL and slow application of the rest – after allowing an interval of at least 20 – 30 seconds later.

Opened cartridges must not be used in other patients. Residues must be discarded (see section 6.6).

**4.3 Contraindications**

Xylestesin-A must not be used in the event of
- hypersensitivity to the active substances, sodium sulphite (E221) or to any of the excipients listed in section 6.1,
Due to the active substance lidocaine (lignocaine), Xylestesin-A must not be used in the event of
– known allergy or hypersensitivity to local anaesthetics of the amide type,
– severe, uncontrolled or untreated excitation and conduction disorders of the heart (e.g. grade II and III AV block, pronounced bradycardia),
– acutely decompensated heart failure,
– severe hypotension

Due to the content of adrenaline (epinephrine) as a vasoconstrictor admixture, Xylestesin-A must not be used in the event of
– Heart diseases such as:
  - unstable angina pectoris,
  - recent myocardial infarction,
  - recent coronary artery bypass surgery,
  - refractory arrhythmia and paroxysmal tachycardia or high-frequency, continuous arrhythmia,
  - untreated or uncontrolled severe hypertension,
  - untreated or uncontrolled congestive heart failure,
– concomitant treatment with monoamine oxidase (MAO) inhibitors or tricyclic antidepressants (see section 4.5).
– Xylestesin-A is not allowed to be used in acra of extremities

Due to the content of sulphite as excipient, Xylestesin-A must not be used in the event of
– allergy or hypersensitivity to sulphite,
– severe bronchial asthma.

Xylestesin-A can provoke acute allergic reactions with anaphylactic symptoms (e.g. bronchospasm).

4.4 Special warnings and precautions for use

Special warnings

Xylestesin-A must be used with particular caution in the event of
– severe impairment to the renal and hepatic function,
– angina pectoris (see section 4.2 and 4.3),
– arteriosclerosis,
– considerably impaired blood coagulation or concomitant treatment with anticoagulants or platelet aggregation inhibitors. The overall risk of bleeding is increased.
– haemorrhagic diatheses – increased bleeding risk particularly with nerve-block anaesthesia,
– uncontrolled or untreated hyperthyroidism,
– narrow-angle glaucoma,
– diabetes mellitus,
– lung diseases – particularly allergic bronchial asthma,
- pheochromocytoma,
- methaemoglobinaemia,
- impaired cardiovascular function due to decreased ability to compensate prolonged A-V conduction,
- epilepsy (Avoid high doses!),
- blood screening tests on athletes as Xylestesin-A may show up positive results.

Lidocaine (lignocaine) is not listed in the current WADA list. The listed adrenaline (epinephrine) can be used in local anaesthetics.

This medicinal product contains less than 1 mmol (23 mg) sodium per 1.7 mL, i.e. essentially “sodium free”.

**Precautions for use:**

- Information to the patients: The patient should be advised to exert caution to avoid inadvertent trauma to the lips, tongue, cheek mucosae or soft palate while these structures are anaesthetised. The patient should therefore avoid eating until the anaesthetic has worn off.

- The lower blood flow in the pulp tissue due to the content of adrenaline (epinephrine) and thus the risk of overlooking an opened pulp, has to be taken into account regarding cavity or crown preparations.

- Injection into an inflamed area should be avoided. The reduced penetration of lidocaine (lignocaine) into inflamed tissue can result in failure of anaesthesia.

- Inadvertent intravascular application must be avoided (see section 4.2). Accidental intravascular injection or accidental overdose may be associated with convulsions, followed by central nervous system depression or cardiorespiratory arrest (see section 4.9).

- Dental practitioners who employ local anaesthetic agents should be well versed in diagnosis and management of emergencies which may arise from their use.

- Each time a local anaesthetic is used the following medicines/therapy as well as an indwelling venous cannula set should be available:
  - Anti-convulsant medicines (benzodiazepines e.g. diazepam), muscle relaxants, glucocorticoids, atropine and vasopressors or adrenaline (epinephrine) as well as an electrolyte solution for a severe allergic or anaphylactic reaction.
  - Resuscitating equipment (in particular a source of oxygen) enabling artificial ventilation if necessary.

- Cardiovascular and respiratory (adequate oxygen supply) vital signs and the patient's state of consciousness should be carefully and constantly monitored after each local anaesthetic injection. Restlessness, anxiety, tinnitus, dizziness, visual disturbances, tremors,
depression, or drowsiness may be early warning signs of central nervous system toxicity (see section 4.9).

4.5 Interaction with other medicines and other forms of interaction

Interactions affecting the use of this medicine:

- Contraindications of concomitant use:
  
  **Patients taking MAO inhibitors or tricyclic antidepressants**
  The sympathomimetic effect of adrenaline (epinephrine) can be intensified by the simultaneous intake of MAO inhibitors or tricyclic antidepressants (see also section 4.3).

- Concomitant use is not recommended in:
  
  **Patients taking phenothiazines and butyrophenones**
  Phenothiazines and butyrophenones may reduce or reverse the pressor effect of adrenaline (epinephrine). Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.

**Patients taking non-selective beta-blockers**

The concomitant administration of non-cardioselective β-blockers can lead to an increase in blood pressure due to the adrenaline (epinephrine) in Xylestesin-A.

**Inhalational anaesthetics**

Certain inhalational anaesthetics, such as halothane, can sensitize the heart to catecholamines and therefore induce arrhythmias following administration of Xylestesin-A.

The use of Xylestesin-A during or following treatment with general anaesthesia should be avoided, if possible.

**Patient taking vasopressor and ergot-type oxytocic medicines**

Lidocaine (lignocaine) hydrochloride with adrenaline (epinephrine) 1:80,000 or other vasopressors should not be used concomitantly with ergot-type oxytocic medicines, because a severe persistent hypertension may occur.

Precaution including dose adjustment:

**Local anaesthetics**

Caution is advised if lidocaine (lignocaine) with adrenaline (epinephrine) is used concurrently with other local anaesthetics. The toxic effects of local anaesthetics are additive.

Interactions resulting in clinically relevant changes on the use of other medicines:

- Concomitant use is not recommended in:
  
  **Patients taking oral antidiabetics**
  Adrenaline (epinephrine) can inhibit insulin release in the pancreas and thus diminish the effect of oral antidiabetics.
Paediatric population
No significant differences can be expected between adult and paediatric populations with regard to medicine interactions.

4.6 Fertility, pregnancy and lactation

Pregnancy
There is limited data available on the use of Xylestesin-A in pregnant women. Lidocaine (lignocaine) animal studies do not indicate directly or indirectly harmful effects with respect to reproductive toxicity (see section 5.3). Animal studies carried out with adrenaline (epinephrine) have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Caution should be exercised when administering to pregnant women. Xylestesin-A should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Breast-feeding
A small ratio of lidocaine (lignocaine) is excreted into the breast milk but no effects on breast-fed neonates are likely at therapeutic doses. It is not known whether adrenaline (epinephrine) is excreted into the breast milk.

A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Xylestesin-A should be made taking into account the benefit of breast-feeding to the child and the benefit of Xylestesin-A therapy to the woman. Therefore, following anaesthesia with Xylestesin-A, breast-feeding mothers should discard the first human milk output before resuming breast-feeding.

Fertility
Animal studies with high doses of lidocaine (lignocaine) or adrenaline (epinephrine) showed an effect on fertility (see section 5.3). At therapeutic lidocaine (lignocaine) doses of Xylestesin-A, however, no effects on male or female fertility are likely.

4.7 Effects on the ability to drive and use machines

In sensitive patients, injection of Xylestesin-A can lead to a transient impairment of responsiveness, e.g. when driving a vehicle. The physician must decide on an individual basis whether the patient may drive or operate machinery. The patient should not leave the dental practice earlier than 30 minutes after the injection.

4.8 Undesirable effects

a) Summary of the safety profile:

In general, the therapeutic use of Xylestesin-A can be regarded as very safe. The causality assessment in case of adverse events is difficult, as they may be due to the underlying dental
disease, the dental procedure or the local anaesthetic and a clear differentiation is not possible. The description of the safety profile of Xylestesin-A is based on data identified in published clinical studies and on the postmarketing surveillance data of the manufacturer. In clinical studies, the most frequently observed adverse events were hypoesthesia oral (74%), followed by medicine ineffective (8.5%) as well as pain, procedural pain, toothache (0.25-1.26%). With the exception of oral hypoesthesia, no nerve disturbances were observed in clinical studies, which may be explained by the low patient numbers. Postmarketing surveillance data confirm the pattern described in published clinical studies in general, but indicated a lower overall incidence of adverse events. However, it has to be considered that spontaneous reporting systems do not allow incidence calculation. The overall risk of nerve disturbances (e.g. hypoesthesia, paraesthesia, taste disorders) is low according to the postmarketing experience. In the case of suspected hypersensitivity reactions, allergy testing is recommended including testing of the single components of the medicine.
**b) Tabulated summary of adverse reactions:**

The tabulated summary is based on data from published controlled clinical studies (N = 1,990 patients) and completed by postmarketing data (5-years-interval):

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Very common (&gt; 1/10)</th>
<th>Common (≥ 1/100, &lt; 1/10)</th>
<th>Uncommon (≥ 1/10’000, &lt; 1/100)</th>
<th>Rare (≥ 1/10’000, &lt; 1/1’000)</th>
<th>Very rare (&lt; 1/10’000)</th>
<th>Not known (frequency cannot be estimated from the available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td><strong>Uncommon</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral herpes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immune system disorders</td>
<td><strong>Not known</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>anaphylactic reaction, anaphylactic shock, type I hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td><strong>Not known</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>confusional state</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td><strong>Uncommon</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>dizziness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Rare</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Head ache, somnolence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Not known</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>facial palsy, paresis, syncope, dysarthria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eye disorders</td>
<td><strong>Not known</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>accommodation disorder, blindness, diplopia, eye swelling, vision blurred, eyelid ptosis, mydriasis, ophthalmoplegia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td><strong>Rare</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>palpitations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular disorders</td>
<td><strong>Rare</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>haematoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Not known</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>pallor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorder</td>
<td><strong>Not known</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>bronchospasm, laryngeal oedema, respiratory failure, throat tightness, wheezing, dyspnoea, cough</td>
</tr>
</tbody>
</table>
| **Gastrointestinal disorders** | Very common  
oral hypoesthesia |  
Uncommon  

toothache, nausea |  
Not known*  
tongue oedema, vomiting |
| **Skin and subcutaneous tissue disorders** | Rare  

haemorrhage subcutaneous |  
Not known*  
dermatitis bullous, dermatitis contact,  
hypoesthesia facial, pruritus, rash, swelling face, urticaria |
| **General disorders and administration site conditions** | Common  

medicine ineffective, pain |  
Uncommon  
injection site swelling, injection site haematoma |
| **Investigations** | Not known*  
allergy test positive, heart rate increased, heart rate irregular |
| **Injury, poisoning and procedural complications** | Uncommon  

procedural pain, mouth injury |

* data from postmarketing surveillance representing 5 years of observation

c) **Description of selected adverse events:**

Two types of adverse events are of special clinical interest, but not the most frequently reported adverse events. The presentation is based mainly on postmarketing surveillance data.

**Nerve disturbances**

Nerve disturbances in dentistry may have different reasons, caused by underlying dental disease, by the dental procedure, but also by direct adverse events of dental local anaesthetics. With an observation frequency of one event per 10 million of sold cartridges the risk of such disturbances is low. In the data compilation given above the most frequently reported nerve disturbance in clinical studies was oral hypoesthesia (mainly lip numbness). It should be taken into account that the high number of oral hypoesthesia reported in clinical studies may reflect only an individually increased duration of action of Xylestesin-A. During postmarketing surveillance, cases of facial palsy, hypoesthesia facial and different adverse events affecting the eye (e.g. diplopia, accommodation disturbances) were identified indicating possibly anaesthesia related nerve disturbances. All of these adverse events were reversible.
Hypersensitivity reactions

Hypersensitivity reactions were only rarely identified in the postmarketing surveillance (6.41 events per 10 millions sold cartridges). Mostly the reactions were non-serious (4.56/10 millions sold cartridges), but life-threatening reactions cannot be fully excluded. The reactions included anaphylactic reactions/shock, skin reactions and respiratory symptoms. In the case of suspected hypersensitivity reaction, allergy testing is recommended including testing of the single components of the medicinal product. Sodium sulfite (E221): May rarely cause severe hypersensitivity reactions and bronchospasm.

d) Paediatric population

The observation during postmarketing surveillance does not reveal differences in the safety profile in children compared with those in adults.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions http://nzphvc.otago.ac.nz/reporting/.

4.9 Overdose

Acute emergencies from local anaesthetics are generally related to high plasma levels encountered during therapeutic use or unintended and rapid intravascular administration of local anaesthetics. Symptoms of overdose may appear either immediately, caused by accidental intravascular injection or abnormal absorption conditions, e.g. in inflamed or well vascularised tissue, or later, caused by genuine overdose following an injection of excessive quantity of anaesthetic solution, and manifest themselves as central nervous and/or vascular symptoms.

No case of overdose has been reported during post-marketing surveillance.

Symptoms probably caused by lidocaine (lignocaine):

Cardiovascular symptoms (SOC Cardiac disorders, Vascular disorders, Investigations): blood pressure decreased, bradycardia, cardiac arrest, conduction disorder.

Central nervous symptoms (SOC Psychiatric disorders, Nervous system disorders, Ear and labyrinth disorders, Gastrointestinal disorders, Musculoskeletal and connective tissue disorders, Investigations): anxiety, coma, confusional state, dizziness, dysgeusia, grand mal convolution, muscle twitching, nausea, respiratory paralysis, respiratory rate increased, restlessness, somnolence, tinnitus, tremor, vomiting.

The most dangerous symptoms regarding the outcome of such an event are: blood pressure decreased, cardiac arrest, conduction disorder, grand mal convulsions, respiratory paralysis and somnolence/coma.
Symptoms probably caused by adrenaline (epinephrine):

Pressure symptoms (SOC Vascular disorders, Investigations): blood pressure systolic increased, blood pressure diastolic increased, venous pressure increased, pulmonary arterial pressure increased, hypotension.

Cardiac symptoms (SOC Cardiac disorders): bradycardia, tachycardia, arrhythmia (eg. atrial tachycardia, atrioventricular block, ventricular tachycardia, premature ventricular contractions).

These symptoms can result in life threatening situations as well as pulmonary oedema, cardiac arrest, kidney failure, and metabolic acidosis.

**Therapy**

If symptoms of overdose arise the application of the local anaesthetic has to be stopped.

General basic measures:
Diagnostics (respiration, circulation, consciousness), resuscitation and/or maintenance of the vital functions (respiration and circulation), administration of oxygen, intravenous access.

Special measures:
Hypertension: Elevation of the upper body, if necessary sublingual nifedipine.

Convulsions: Protect patients from concomitant injuries, if necessary benzodiazepines (e.g. diazepam iv).

Hypotension: Horizontal position, if necessary intravascular infusion of a whole electrolyte solution, vasopressors (e.g. etilefrine iv).

Bradycardia: Atropine iv.

Anaphylactic shock: Contact emergency physician, in the meantime shock positioning, generous infusion of a physiological electrolyte solution, if necessary adrenaline (epinephrine) iv., cortisone iv.

Cardiovascular arrest: Immediate cardiopulmonary resuscitation, contact emergency physician.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
**Pharmacotherapeutic group:** Anaesthetics, local, ATC code N01B B52

**Mechanism of action:**
Xylestesin-A contains lidocaine (lignocaine) which is a local anaesthetic of the amide type used in dentistry and leads to a reversible inhibition of the irritability of vegetative, sensory and motor nerve fibres. The blocking of voltage dependent Na⁺ channels on the membrane of the nerve fibre is supposed to be the mechanism of action of lidocaine (lignocaine). Adrenaline (epinephrine) leads locally to vasoconstriction and reduced blood supply, whereby the absorption of lidocaine (lignocaine) is delayed. The result is a higher concentration of the local anaesthetic at the site of action, over a longer period, as well as the reduction of systemic adverse side effects.

**Pharmacodynamic effects:**
Onset of local anaesthetic effects of Xylestesin-A occurs after a short latency period of 1-3 min with infiltration and after somewhat longer latency period with nerve block anaesthesia (2 to 4 minutes after injection). The duration of complete anaesthesia with Xylestesin-A in pulpal anaesthesia is 30 to 60 minutes, and in soft-tissue anaesthesia 120 to 180 minutes.

**Clinical efficacy and safety:**
Success rates of anaesthesia with Xylestesin-A differ, depending on the type of anaesthesia and the above-mentioned factors. In general, success rates of about 90% or higher may be expected after single use if the medicine is administered as indicated. The inferior alveolar nerve block has the greatest failure rate. Repeated or supplementary injections may be necessary in the event of failed anaesthesia or in the event of prolonged dental procedures and surgery. Particular circumstances, e.g. acute irreversible pulpitis of mandibular molars, may require special or alternative anaesthetic techniques. Articaine 4% with adrenaline (epinephrine) may provide better clinical efficacy in such cases as reported by different authors. Although Xylestesin-A is usually tolerated, adverse reactions cannot be fully excluded (see section 4.8), particularly in the event of overdose (see section 4.9).

**Paediatric population:**
The use of Xylestesin-A in the paediatric population is considered for routine treatment. Dosages in the paediatric population should be reduced taking into account age, body weight, physical condition and the magnitude of the treatment (see section 4.2), together with complex measures to prevent a painful experience and to reduce anxiety, including sedation. Since paediatric patients relatively often suffer traumatic injury to their still (residual) anaesthetised soft tissue following local anaesthesia administration in the dental practice (reportedly 13% of all cases), local anaesthesia providing the appropriate duration of efficacy should be used.

**5.2 Pharmacokinetic properties**

**Absorption:**
Xylestesin-A is rapidly and extensively absorbed. The maximum plasma level of lidocaine (lignocaine) from intraoral injection is achieved after 10 – 20 minutes. Exogenously administered adrenaline (epinephrine), including in dental use, may increase the adrenaline
(epinephrine) serum concentration in a dose dependent manner with a decline within a few minutes after administration.

**Distribution:**
Lidocaine (lignocaine) is bound up to 60 to 80 % in the serum to plasma proteins. Lidocaine (lignocaine) and adrenaline (epinephrine) are widely distributed within the organism.

**Biotransformation and elimination:**
Lidocaine (lignocaine) is largely metabolised in the liver and any alteration in liver function or hepatic blood flow can have a significant effect on its pharmacokinetics and dosage requirements. Metabolism in the liver is rapid and about 90 % of the given dose is dealkylated to form monoethylglycinexylidide and glycinexylidide. Less than 10 % is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The elimination half-life is 1.5 to 2 hours.
Lidocaine (lignocaine) crosses the blood-brain and placental barriers.
Adrenaline (epinephrine) is rapidly catabolised in the liver and other tissues. The metabolites are excreted renally.

**Special populations:**
*Effect of age:* Lidocaine (lignocaine) has been extensively investigated in elderly patients. A significantly longer half-life was found for lidocaine (lignocaine) in elderly patients. Reduced clearance was detected only in elderly men, while the values in elderly women did not differ significantly from younger individuals. Dose reduction was sometimes suggested for elderly patients (reduction by approximately 1/3 to ½).
According to the age of the child, differences compared with adults regarding metabolism and distribution volume should be considered.
For children it seems preferable to use medicines with higher protein binding and a faster metabolism such as articaine.

*Renal and hepatic insufficiency:*
The elimination half-life of lidocaine (lignocaine) following an intravenous bolus injection is typically 1.5 to 2.0 hours. Because of the rapid rate at which lidocaine (lignocaine) is metabolised, any condition that affects liver function may alter lidocaine (lignocaine) kinetics. The half-life may be more than doubled in patients with liver dysfunction. Renal dysfunction does not affect lidocaine (lignocaine) kinetics but may increase the accumulation of metabolites.

### 5.3 Preclinical safety data

There is evidence that 2,6-xylidine, a metabolic product arising from lidocaine (lignocaine), can have mutagenic effects in the rat, and possibly also in man. This evidence is obtained from in-vitro tests in which the said metabolite was used at very high, almost toxic concentrations. There is no reason to believe at this time that the parent substance, lidocaine (lignocaine), is itself also mutagenic.
A carcinogenicity study of transplacental exposure and postnatal treatment of animals for two years with 2,6-xylidine in rats demonstrated malignant and benign tumors predominantly in the nasal cavities (ethmoturbinalia) by means of this highly sensitive test system (transplacental exposure and postnatal treatment of animals for two years with very
high doses). It does not seem totally unlikely that these findings will be relevant to humans. For this reason, high doses of Xylestesin-A (lidocaine (lignocaine)) should not be administered over longer periods. Lidocaine (lignocaine) has evidently no teratogenic potential if used in recommended doses (see section 4.6). Adrenaline (epinephrine) was potentially teratogenic in rats albeit at doses 25 times the human therapeutic dose (see section 4.6).

While supratherapeutic doses of lidocaine (lignocaine) and adrenaline (epinephrine) administered under in vitro or in vivo experimental conditions to laboratory animals may affect fertilisation and foetal development, harmful or other effects on female or male fertility is not expected based on animal studies at therapeutic doses of lidocaine (lignocaine) and adrenaline (epinephrine) (see section 4.6).

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sodium sulfite (E221)
Sodium chloride
Hydrochloric acid 14% (for pH adjustment)
Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicine must not be mixed with other medicines.

6.3 Shelf-life

2 years

6.4 Special precautions for storage

Do not store above 25°C. Store in the original package in order to protect from light.

6.5 Nature and contents of container

Cartridge made of colourless neutral glass I.
Stopper and rubber disc are made of butyl rubber.
Green coloured aluminium cap made of aluminium-iron-silicon-alloy.

Tin with 50 cartridges of 1.7 mL each.
Tin with 50 cartridges of 2.2 mL each (not-marketed).

6.6 Special precautions for disposal and other handling
Prior to administration, the product should be inspected visually for particulate matter, discolouration or damage to the container. The product should not be used if such defects are observed.

The product is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

3M New Zealand Ltd
94 Apollo Drive,
Rosedale
Auckland
Telephone: 09 477 4040

9 DATE OF FIRST APPROVAL

14 August 1984

10 DATE OF REVISION OF THE TEXT

20 December 2018
<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, 4.2, 4.5, 7, 8, 9, 10</td>
<td>Updated section headings as per NZ DS template</td>
</tr>
<tr>
<td>2</td>
<td>Updated active ingredient description as per international harmonisation of medicine ingredient names: Updated active ingredients Lidocaine hydrochloride to Lidocaine (lignocaine) hydrochloride (as monohydrate) and active ingredient Epinephrine (adrenaline) hydrochloride to Adrenaline (epinephrine) hydrochloride throughout entire document. For clarity we have also indicated the adrenaline (epinephrine) content.</td>
</tr>
<tr>
<td>4.2</td>
<td>Rewording in accordance with CCDSv3</td>
</tr>
<tr>
<td>4.4</td>
<td>Removed examples heparin and acetylsalicylic acid as many different molecules available on the market. Updated term ‘allergic asthma bronchiale’ to ‘allergic bronchial asthma’; spelling correction methaemoglobinaemia; sodium sulphite hypersensitivity statement moved to Section 4.8; myorelaxants updated to muscle relaxants, blurred vision updated to visual disturbances, and rewording in accordance with CCDSv3</td>
</tr>
<tr>
<td>4.5</td>
<td>Removal of statement re excessive plasma concentrations under subsection ‘Precaution including dose adjustment – Local anaesthetics’ as per CCDSv3</td>
</tr>
<tr>
<td>4.6</td>
<td>Additional information added to Pregnancy, Breast-feeding and Fertility subsections as per CCDSv3</td>
</tr>
<tr>
<td>4.7</td>
<td>Additional statements added in accordance with CCDSv3</td>
</tr>
<tr>
<td>4.8</td>
<td>a) Rewording as per CCDSv3 b) SOC Injury, poisoning and procedural complications updated to include procedural pain and mouth injury as uncommon adverse effects c) carpules reworded to cartridges, addition of sodium sulphite statement re hypersensitivity previously located in Section 4.4</td>
</tr>
<tr>
<td>4.9</td>
<td>Reworded as per CCDSv3; Addition of mandatory ‘Management of Overdose’ statement as per NZ DS template</td>
</tr>
<tr>
<td>5.1, 5.2</td>
<td>Reworded as per CCDSv3</td>
</tr>
<tr>
<td>6.1</td>
<td>Excipient ‘anhydrous sodium sulfite’ updated to ‘sodium sulfite’ as per TPDR and recognised international harmonised name (IHN)</td>
</tr>
<tr>
<td>6.2</td>
<td>Incompatibility statement reworded as per NZ DS template</td>
</tr>
<tr>
<td>6.5</td>
<td>Added non-marketed 2.2ml cartridge presentation as per TPDR and NZ DS template</td>
</tr>
<tr>
<td>6.6</td>
<td>Reworded in accordance with CCDSv3. Disposal statement reworded as per NZ DS template</td>
</tr>
<tr>
<td>8</td>
<td>Sponsor address updated</td>
</tr>
<tr>
<td>9</td>
<td>Date of first approval added as per TPDR</td>
</tr>
<tr>
<td>10</td>
<td>Date of revision updated to 20 December 2018</td>
</tr>
</tbody>
</table>